[{"address1": "345 Park Avenue South", "address2": "6th Floor", "city": "New York", "state": "NY", "zip": "10010", "country": "United States", "phone": "212 547 9879", "website": "https://www.lexeotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. R. Nolan Townsend", "age": 43, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 3741748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Adler M.D.", "age": 50, "title": "Chief Medical Officer & Head of Research", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 2705659, "exercisedValue": 0, "unexercisedValue": 112845}, {"maxAge": 1, "name": "Dr. Jose Manuel Otero Ph.D.", "age": 45, "title": "Chief Technical Officer", "yearBorn": 1979, "fiscalYear": 2024, "totalPay": 2987030, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald G. Crystal M.D.", "title": "Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Louis  Tamayo", "age": 48, "title": "CFO & Principal Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jenny R. Robertson J.D.", "age": 49, "title": "Chief Legal Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 617900, "exercisedValue": 0, "unexercisedValue": 94692}, {"maxAge": 1, "name": "Mr. Jordan M. Baumhardt Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sandi See Tai M.D.", "age": 53, "title": "Chief Development Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  DiRisio", "title": "Senior Vice President of Development Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  McHenry", "title": "VP & Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.43, "open": 9.6, "dayLow": 9.3, "dayHigh": 10.08, "regularMarketPreviousClose": 9.43, "regularMarketOpen": 9.6, "regularMarketDayLow": 9.3, "regularMarketDayHigh": 10.08, "payoutRatio": 0.0, "forwardPE": -3.6137185, "volume": 1033450, "regularMarketVolume": 1033450, "averageVolume": 866679, "averageVolume10days": 1115420, "averageDailyVolume10Day": 1115420, "bid": 9.93, "ask": 10.08, "bidSize": 2, "askSize": 3, "marketCap": 720419392, "fiftyTwoWeekLow": 1.45, "fiftyTwoWeekHigh": 11.72, "allTimeHigh": 22.33, "allTimeLow": 1.45, "fiftyDayAverage": 6.871, "twoHundredDayAverage": 4.592925, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 416533856, "profitMargins": 0.0, "floatShares": 37838669, "sharesOutstanding": 71969964, "sharesShort": 7315216, "sharesShortPriorMonth": 5891889, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.1355, "heldPercentInsiders": 0.00449, "heldPercentInstitutions": 0.76623, "shortRatio": 5.8, "shortPercentOfFloat": 0.14850001, "impliedSharesOutstanding": 71969964, "bookValue": 2.56, "priceToBook": 3.9101565, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -114172000, "trailingEps": -3.21, "forwardEps": -2.77, "enterpriseToEbitda": -3.391, "52WeekChange": 0.21480584, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 10.01, "targetHighPrice": 30.0, "targetLowPrice": 9.0, "targetMeanPrice": 19.55556, "targetMedianPrice": 20.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 132893000, "totalCashPerShare": 2.461, "ebitda": -122818000, "totalDebt": 8913000, "quickRatio": 4.206, "currentRatio": 4.433, "debtToEquity": 6.449, "returnOnAssets": -0.41912997, "returnOnEquity": -0.7532, "grossProfits": -73681000, "freeCashflow": -53553000, "operatingCashflow": -95067000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "LXEO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "shortName": "Lexeo Therapeutics, Inc.", "longName": "Lexeo Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1761951982, "regularMarketTime": 1761940800, "exchange": "NGM", "messageBoardId": "finmb_625814286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 6.15058, "regularMarketPrice": 10.01, "postMarketChangePercent": 1.4984976, "postMarketPrice": 10.16, "postMarketChange": 0.14999962, "regularMarketChange": 0.58, "regularMarketDayRange": "9.3 - 10.08", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 866679, "fiftyTwoWeekLowChange": 8.56, "fiftyTwoWeekLowChangePercent": 5.9034486, "fiftyTwoWeekRange": "1.45 - 11.72", "fiftyTwoWeekHighChange": -1.71, "fiftyTwoWeekHighChangePercent": -0.14590444, "fiftyTwoWeekChangePercent": 21.480583, "earningsTimestamp": 1754884800, "earningsTimestampStart": 1762950600, "earningsTimestampEnd": 1762950600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.21, "epsForward": -2.77, "epsCurrentYear": -2.45094, "priceEpsCurrentYear": -4.0841475, "fiftyDayAverageChange": 3.1390004, "fiftyDayAverageChangePercent": 0.4568477, "twoHundredDayAverageChange": 5.417075, "twoHundredDayAverageChangePercent": 1.1794391, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-11-03", "averageAnalystRating": "1.3 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1699018200000, "marketState": "CLOSED", "displayName": "Lexeo Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]